Novartis Q1 Results Miss Expectations as Core EPS Falls Below Market Estimates
Novartis AG reported its Q1 2025 earnings with core EPS of $1.99, falling short of the $2.10 market estimate. Net sales …
4 articles about 'Drug Development'
Novartis AG reported its Q1 2025 earnings with core EPS of $1.99, falling short of the $2.10 market estimate. Net sales …
India's largest pharmaceutical company Sun Pharma has announced an all-cash acquisition of U.S. drugmaker Organon for ap…
Multimodal Biological Foundation Models (BioFMs) are accelerating end-to-end transformation from drug discovery to clini…
Google DeepMind has achieved a major new breakthrough in protein folding, with its AI model predicting three-dimensional…